Milestone Pharmaceuticals Inc.(MIST)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MIST Milestone Pharmaceuticals Inc.

交易中 09-17 12:21:06 EDT

0.9181

+0.0289

+3.25%

最高0.9386	最低0.9086	成交量64.33万
今开0.9200	昨收0.8892	日振幅3.37%
总市值1.14亿	流通市值9,775万	总股本1.24亿
成交额59.06万	换手率0.60%	流通股本1.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MIST","market":"US","secType":"STK","nameCN":"Milestone Pharmaceuticals Inc.","latestPrice":0.9181,"timestamp":1789661925081,"preClose":0.8892,"halted":0,"volume":643304,"delay":0,"changeRate":0.03250112460638781,"floatShares":106471476,"shares":124000000,"eps":-0.6747981,"marketStatus":"交易中","change":0.0289,"latestTime":"09-17 12:21:06 EDT","open":0.92,"high":0.9386,"low":0.9086,"amount":590640.02740168,"amplitude":0.033738,"askPrice":0.9179,"askSize":1,"bidPrice":0.9161,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.6747981,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":0.8892,"preHourTrading":{"tag":"盘前","latestPrice":0.9399,"preClose":0.8892,"latestTime":"09:16 EDT","volume":6869,"amount":6326.8854689,"timestamp":1789650993442,"change":0.0507,"changeRate":0.057018,"amplitude":0.044872},"postHourTrading":{"tag":"盘后","latestPrice":0.89,"preClose":0.8892,"latestTime":"19:49 EDT","volume":18609,"amount":16645.31711,"timestamp":1789602559429,"change":0.0008,"changeRate":0.0009,"amplitude":0.012146},"volumeRatio":0.692556,"impliedVol":3.6051,"impliedVolPercentile":0.8884},"requestUrl":"/m/hq/s/MIST","defaultTab":"news","newsList":[{"id":"1140066454","title":"里程碑医药在华获批触发200万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1140066454","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140066454?lang=zh_cn&edition=full","pubTime":"2026-09-03 23:00","pubTimestamp":1788447612,"startTime":"0","endTime":"0","summary":"9月3日（路透社）——Milestone Pharmaceuticals Inc.今日宣布，其用于治疗阵发性室上性心动过速的依曲帕米鼻喷雾剂已获得中国国家药品监督管理局的批准。此项批准具有里程碑意义，标志着依曲帕米首次在美国以外的地区获得监管许可。该公司进一步披露，NMPA的此次批准触发了云顶新耀应向Milestone Pharmaceuticals支付的200万美元里程碑付款。Milestone Pharmaceuticals表示，依照与云顶新耀的协议条款，该公司在大中华区有资格获得高达9800万美元的里程碑付款，以及最高可达18%的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","01952","BK1161","BK1574","BK1583","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136236303","title":"里程碑制药与 Everest 达成协议，在大中华区可获最高 9800 万美元里程碑付款及 18% 特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1136236303","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136236303?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:37","pubTimestamp":1788442670,"startTime":"0","endTime":"0","summary":"里程碑制药公司（Milestone Pharmaceuticals）宣布，根据与 Everest 公司签署的协议条款，该公司将有资格在大中华区获得最高达 9800 万美元的里程碑付款，并享有最高 18% 的特许权使用费。这一合作安排标志着双方在大中华区市场的战略布局正式落地，为里程碑制药在该区域的商业化进程提供了重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130878606","title":"里程碑制药与 Everest Medicines 达成独家许可：依曲帕米鼻喷雾剂登陆大中华区","url":"https://stock-news.laohu8.com/highlight/detail?id=1130878606","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130878606?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:37","pubTimestamp":1788442664,"startTime":"0","endTime":"0","summary":"里程碑制药携手 Everest Medicines，正式敲定了一项重大合作。后者手中握有的独家许可权，将依曲帕米鼻喷雾剂全面引入大中华区市场。这项协议，无疑为心血管治疗领域注入了全新的活力。总而言之，里程碑制药与Everest Medicines的此番合作，既是一次资产的明智配置，也是一次对区域市场潜力的殷切押注。随着合作的逐步深化，依曲帕米鼻喷雾剂能否在大中华区书写出亮眼的答卷，值得拭目以待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164485145","title":"里程碑医药：中国国家药监局批准触发200万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1164485145","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164485145?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:36","pubTimestamp":1788442598,"startTime":"0","endTime":"0","summary":"里程碑医药公司迎来重大进展——中国国家药品监督管理局的相关批准，正式触发了高达200万美元的里程碑付款。这一关键节点，标志着公司在监管审批道路上又迈出了坚实一步。200万美元的里程碑付款，正是对阶段性成就的直接肯定。对里程碑医药而言，这笔资金将为其持续推进研发和市场布局提供有力支持。未来，随着更多监管节点的达成，里程碑付款机制将持续为公司注入流动性，助力其在竞争激烈的医药领域稳健前行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112591129","title":"里程碑制药启动Etripamil鼻喷雾剂关键性III期临床试验，用于心房颤动伴快速心室率（Afib-Rvr）的自我给药治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1112591129","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112591129?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:01","pubTimestamp":1787313718,"startTime":"0","endTime":"0","summary":"里程碑制药公司宣布，正式启动一项关键性的III期临床试验，评估其研发的Etripamil鼻喷雾剂在心房颤动伴快速心室率患者中的疗效与安全性。该试验的核心亮点在于，这款药物专为患者自我给药设计，旨在为这一常见心律失常提供一种全新的、便捷的治疗选择。若试验结果积极，将有望为全球数百万深受Afib-Rvr困扰的患者带来颠覆性的自我管理方案，显著改善其生活质量与疾病预后。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151557571","title":"里程碑制药：正寻求以单研究补充新药申请（sNDA）注册途径治疗房颤伴快速心室率","url":"https://stock-news.laohu8.com/highlight/detail?id=1151557571","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151557571?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:01","pubTimestamp":1787313670,"startTime":"0","endTime":"0","summary":"里程碑制药公司（Milestone Pharmaceuticals）目前正积极推进一项战略布局，旨在通过单一研究的补充新药申请（sNDA）注册路径，为其在房颤伴快速心室率（Afib-RVR）适应症上的候选药物铺平上市之路。此举标志着该公司在心血管治疗领域迈出了关键一步，力图以精简而高效的监管策略加速产品抵达患者手中。值得注意的是，这一路径的选择反映出公司对现有临床数据充分性的信心，同时也预示着其商业化进程可能迎来实质性突破。在当前竞争激烈的市场环境下，这一决策无疑具有深远的战略意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142907425","title":"里程碑制药公布2026年第二季度财务业绩并发布企业最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1142907425","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142907425?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:09","pubTimestamp":1786532949,"startTime":"0","endTime":"0","summary":"里程碑制药公司（Milestone Pharmaceuticals Inc.）今日正式披露了其2026年第二季度的财务数据，同时向市场同步更新了公司近期的运营进展与战略部署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110975987","title":"Milestone Pharmaceuticals Inc. 拟通过Cantor Fitzgerald销售协议发行至多1亿美元普通股 - SEC备案文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1110975987","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110975987?lang=zh_cn&edition=full","pubTime":"2026-05-14 05:31","pubTimestamp":1778707868,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件披露，Milestone Pharmaceuticals Inc. 可能通过其与Cantor Fitzgerald & Co. 达成的股权分销销售协议，发行并出售价值最高达1亿美元的普通股。\n该份备案文件显示，此次股份发行将依据一份市场销售协议执行。公司计划将此次发行所得的净收益用于一般企业用途，其中可能包括推进产品管线、临床开发、资本支出以及补充营运资金等。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146892283","title":"Milestone Pharmaceuticals公布2026年第一季度财务业绩并更新公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1146892283","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146892283?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:12","pubTimestamp":1778670760,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals Inc. (MIST) 近日披露了其2026年第一季度的财务报告，同时向市场通报了公司近期的业务进展与战略规划。此次发布涵盖了公司在报告期内的运营表现、财务状况以及未来发展方向的关键信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126939961","title":"里程碑制药启动Reset-Psvt登记研究 旨在为Cardamyst™鼻喷雾剂治疗室上速生成真实世界证据","url":"https://stock-news.laohu8.com/highlight/detail?id=1126939961","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126939961?lang=zh_cn&edition=full","pubTime":"2026-04-10 20:01","pubTimestamp":1775822478,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals Inc.（简称里程碑制药）宣布启动一项名为Reset-Psvt的登记研究项目。该项目旨在收集关于其核心产品Cardamyst™（Etripamil）鼻喷雾剂在阵发性室上性心动过速（PSVT）患者群体中应用的真实世界临床数据。通过系统性登记患者使用情况，该研究将为药物在实际临床环境中的疗效与安全性提供重要佐证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130778055","title":"里程碑制药公布2025年第四季度及全年财报 同步更新Cardamyst™（依曲帕米）鼻喷雾剂治疗PSVT的商业化进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1130778055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130778055?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:13","pubTimestamp":1774005201,"startTime":"0","endTime":"0","summary":"里程碑制药公司今日披露2025财年第四季度及全年财务业绩，并通报其针对阵发性室上性心动过速的创新药物Cardamyst商业化推进的最新动态。公司财报显示，在Cardamyst获批上市的关键财年内，研发投入与商业化准备资金流动呈现战略化布局。公司首席执行官表示：\"Cardamyst的商业化落地是里程碑制药向心血管领域迈出的战略一步，现有资金足以支撑我们加速市场渗透。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618008456","title":"Milestone Pharmaceuticals Inc.盘中异动 股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618008456","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618008456?lang=zh_cn&edition=full","pubTime":"2026-03-10 03:39","pubTimestamp":1773085165,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日03时39分，Milestone Pharmaceuticals Inc.股票出现波动，股价急速拉升5.06%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为1.47%。其相关个股中，An2 Therapeutics, Inc.、Relmada Therapeutics, Inc.、Camp4 Therapeutics Corporation涨幅较大，An2 Therapeutics, Inc.、Acurx Pharmaceuticals, Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为207.11%、80.83%、70.55%，振幅较大的相关个股有An2 Therapeutics, Inc.、Camp4 Therapeutics Corporation、Briacell Therapeutics Corp C/Wts ，振幅分别为138.24%、84.76%、66.47%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于心血管药物治疗的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031003392595464a4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031003392595464a4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518222686","title":"Milestone Pharmaceuticals Inc.盘中异动 早盘股价大涨6.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222686","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518222686?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613467,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Milestone Pharmaceuticals Inc.股票出现异动，股价快速上涨6.47%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.59%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为1793.97%、381.32%、45.05%，振幅较大的相关个股有Xencor, Inc.、Y-Mabs Therapeutics, Inc.、Savara, Inc.，振幅分别为99.13%、94.67%、6.60%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于治疗心血管适应症的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021310798a29c84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021310798a29c84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517164681","title":"Milestone Pharmaceuticals Inc.盘中异动 早盘大幅上涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517164681","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517164681?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:45","pubTimestamp":1741272315,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时45分，Milestone Pharmaceuticals Inc.股票出现异动，股价大幅拉升5.05%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.47%。其相关个股中，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1299.07%、269.27%、59.20%，振幅较大的相关个股有Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为33.60%、30.53%、25.56%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于治疗心血管适应症的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224515963c502c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224515963c502c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517332948","title":"Milestone Pharmaceuticals Inc.盘中异动 股价大涨6.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517332948","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517332948?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:45","pubTimestamp":1741185917,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时45分，Milestone Pharmaceuticals Inc.股票出现异动，股价急速上涨6.09%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.83%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为485.44%、266.21%、209.56%，振幅较大的相关个股有Silexion Therapeutics Corp、Aditxt, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 ，振幅分别为26.13%、23.90%、22.67%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于治疗心血管适应症的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224518a260cc73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224518a260cc73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634209","title":"Milestone Pharmaceuticals Inc.盘中异动 早盘急速上涨6.13%报1.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634209?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012316,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Milestone Pharmaceuticals Inc.股票出现波动，股价快速拉升6.13%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.17%、23.41%、22.45%，振幅较大的相关个股有Entero Therapeutics Inc.、Cibus, Inc.、Galmed Pharmaceuticals Ltd.，振幅分别为11.70%、9.55%、9.35%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于治疗心血管适应症的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223156a25d3fd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223156a25d3fd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516705723","title":"Milestone Pharmaceuticals Inc.盘中异动 下午盘股价大跌5.17%报1.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516705723","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516705723?lang=zh_cn&edition=full","pubTime":"2025-03-01 02:15","pubTimestamp":1740766537,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日02时15分，Milestone Pharmaceuticals Inc.股票出现异动，股价快速下跌5.17%。截至发稿，该股报1.65美元/股，成交量55.6161万股，换手率1.04%，振幅7.24%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于治疗心血管适应症的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301021537a258372d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301021537a258372d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514701532","title":"Milestone Pharmaceuticals Inc.盘中异动 股价大跌5.03%报1.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514701532","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514701532?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:17","pubTimestamp":1740496659,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时17分，Milestone Pharmaceuticals Inc.股票出现异动，股价快速下挫5.03%。截至发稿，该股报1.80美元/股，成交量27.3828万股，换手率0.51%，振幅5.81%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.86%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于治疗心血管适应症的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231739abdc89d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231739abdc89d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509708209","title":"Milestone Pharmaceuticals Inc.盘中异动 临近午盘急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509708209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509708209?lang=zh_cn&edition=full","pubTime":"2025-02-07 00:56","pubTimestamp":1738861001,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日00时56分，Milestone Pharmaceuticals Inc.股票出现波动，股价快速拉升5.07%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Lipella Pharmaceuticals Inc.、Geovax Labs Inc C/Wts 29/09/2025、Palatin Technologies, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃，换手率分别为5946.75%、1569.09%、159.86%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Palatin Technologies, Inc.，振幅分别为125.58%、53.02%、49.54%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于治疗心血管适应症的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207005641abc4f274&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207005641abc4f274&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509251110","title":"Milestone Pharmaceuticals Inc.盘中异动 临近收盘股价大涨5.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509251110","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509251110?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:57","pubTimestamp":1738789060,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时57分，Milestone Pharmaceuticals Inc.股票出现异动，股价急速上涨5.53%。截至发稿，该股报2.10美元/股，成交量52.9177万股，换手率0.99%，振幅5.02%。Milestone Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为1.97%。Milestone Pharmaceuticals Inc.公司简介：Milestone Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化用于治疗心血管适应症的etripamil。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045740abc3cc60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045740abc3cc60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIST","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.milestonepharma.com","stockEarnings":[{"period":"1week","weight":-0.169},{"period":"1month","weight":-0.1916},{"period":"3month","weight":-0.316},{"period":"6month","weight":-0.3462},{"period":"1year","weight":-0.544},{"period":"ytd","weight":-0.5598}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0241},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1626},{"period":"1year","weight":0.1425},{"period":"ytd","weight":0.1058}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Milestone Pharmaceuticals Inc.于2003年7月根据魁北克省法律注册成立。该公司是一家生物制药公司，专注于创新心血管药物的开发和商业化。该公司批准的产品CARDAYSTTM（艾曲帕米）鼻喷雾剂在美国上市，是第一个也是唯一一个经美国食品药品监督管理局批准的自行治疗药物，可供患者随时随地使用。该公司继续直接或通过与合作伙伴的合作，寻求负责美国以外地区的监管机构的营销批准。该公司还在开发用于快速心室率房颤适应症的艾曲帕米，或“AFib-RVR”。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.028702},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.116389},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.185975},{"month":4,"riseRate":0.714286,"avgChangeRate":0.241328},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.009071},{"month":6,"riseRate":0.5,"avgChangeRate":0.032213},{"month":7,"riseRate":0.625,"avgChangeRate":0.118255},{"month":8,"riseRate":0.625,"avgChangeRate":0.080236},{"month":9,"riseRate":0.5,"avgChangeRate":-0.018313},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.130693},{"month":11,"riseRate":0.571429,"avgChangeRate":0.153201},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.087166}],"exchange":"NASDAQ","name":"Milestone Pharmaceuticals Inc.","nameEN":"Milestone Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Milestone Pharmaceuticals Inc.(MIST)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Milestone Pharmaceuticals Inc.(MIST)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Milestone Pharmaceuticals Inc.,MIST,Milestone Pharmaceuticals Inc.股票,Milestone Pharmaceuticals Inc.股票老虎,Milestone Pharmaceuticals Inc.股票老虎国际,Milestone Pharmaceuticals Inc.行情,Milestone Pharmaceuticals Inc.股票行情,Milestone Pharmaceuticals Inc.股价,Milestone Pharmaceuticals Inc.股市,Milestone Pharmaceuticals Inc.股票价格,Milestone Pharmaceuticals Inc.股票交易,Milestone Pharmaceuticals Inc.股票购买,Milestone Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Milestone Pharmaceuticals Inc.(MIST)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Milestone Pharmaceuticals Inc.(MIST)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}